Kristina L Bajema1, Robin M Nance1, Joseph A C Delaney1, Ellen Eaton2, Thibaut Davy-Mendez3, Maile Y Karris4, Richard D Moore5, Joseph J Eron3, Benigno Rodriguez6, Kenneth H Mayer7, Elvin Geng8, Cindy Garris9, Michael S Saag2, Heidi M Crane1, Mari M Kitahata1. 1. Department of Medicine, Division of Allergy & Infectious Diseases, University of Washington, Seattle, Washington. 2. Department of Medicine, Division of Infectious Diseases, University of Alabama Birmingham, Birmingham, Alabama. 3. Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina. 4. Department of Medicine, Division of Infectious Diseases & Global Public Health, University of California, San Diego, California. 5. Department of Medicine, Division of Infectious Diseases, Baltimore, Johns Hopkins University, Maryland, USA. 6. Department of Medicine, Division of Infectious Diseases, Case Western Reserve University, Cleveland, Ohio. 7. Department of Medicine, Division of Infectious Diseases, Fenway Health, Boston, Massachusetts. 8. Department of Medicine, Division of Infectious Diseases, University of California San Francisco, San Francisco, California. 9. ViiV Healthcare, Research Triangle Park, North Carolina, USA.
Abstract
OBJECTIVE: Historically, a high burden of resistance to antiretroviral therapy (ART) in heavily treatment-experienced (HTE) persons with HIV (PWH) resulted in limited treatment options (LTOs). We evaluated the prevalence, risk factors, and virologic control of HTE PWH with LTO throughout the modern ART era. DESIGN: We examined all ART-experienced PWH in care between 2000 and 2017 in the Centers for AIDS Research Network of Integrated Clinical Systems cohort. METHODS: We computed the annual prevalence of HTE PWH with LTO defined as having two or less available classes with two or less active drugs per class based on genotypic data and cumulative antiretroviral resistance. We used multivariable Cox proportional hazards models to examine risk of LTO by 3-year study entry periods adjusting for demographic and clinical characteristics. RESULTS: Among 27 133 ART-experienced PWH, 916 were classified as having LTO. The prevalence of PWH with LTO was 5.2-7.5% in 2000-2006, decreased to 1.8% in 2007, and remained less than 1% after 2012. Persons entering the study in 2009-2011 had an 80% lower risk of LTO compared with those entering in 2006-2008 (adjusted hazard ratio 0.20; 95% confidence interval: 0.09-0.42). We found a significant increase in undetectable HIV viral loads among PWH ever classified as having LTO from less than 30% in 2001 to more than 80% in 2011, comparable with persons who never had LTO. CONCLUSION: Results of this large multicenter study show a dramatic decline in the prevalence of PWH with LTO to less than 1% with the availability of more potent drugs and a marked increase in virologic suppression in the current ART era.
OBJECTIVE: Historically, a high burden of resistance to antiretroviral therapy (ART) in heavily treatment-experienced (HTE) persons with HIV (PWH) resulted in limited treatment options (LTOs). We evaluated the prevalence, risk factors, and virologic control of HTE PWH with LTO throughout the modern ART era. DESIGN: We examined all ART-experienced PWH in care between 2000 and 2017 in the Centers for AIDS Research Network of Integrated Clinical Systems cohort. METHODS: We computed the annual prevalence of HTE PWH with LTO defined as having two or less available classes with two or less active drugs per class based on genotypic data and cumulative antiretroviral resistance. We used multivariable Cox proportional hazards models to examine risk of LTO by 3-year study entry periods adjusting for demographic and clinical characteristics. RESULTS: Among 27 133 ART-experienced PWH, 916 were classified as having LTO. The prevalence of PWH with LTO was 5.2-7.5% in 2000-2006, decreased to 1.8% in 2007, and remained less than 1% after 2012. Persons entering the study in 2009-2011 had an 80% lower risk of LTO compared with those entering in 2006-2008 (adjusted hazard ratio 0.20; 95% confidence interval: 0.09-0.42). We found a significant increase in undetectable HIV viral loads among PWH ever classified as having LTO from less than 30% in 2001 to more than 80% in 2011, comparable with persons who never had LTO. CONCLUSION: Results of this large multicenter study show a dramatic decline in the prevalence of PWH with LTO to less than 1% with the availability of more potent drugs and a marked increase in virologic suppression in the current ART era.
Authors: Rachael Jones; Mark Nelson; Mark Bower; Tom Powles; Sundhiya Mandalia; Brian Gazzard; Justin Stebbing Journal: Arch Intern Med Date: 2008-09-22
Authors: Luke C Swenson; Jeong Eun Min; Conan K Woods; Eric Cai; Jonathan Z Li; Julio S G Montaner; P Richard Harrigan; Alejandro Gonzalez-Serna Journal: AIDS Date: 2014-05-15 Impact factor: 4.177
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Viviane D Lima; P Richard Harrigan; Martin Sénécal; Benita Yip; Eric Druyts; Robert S Hogg; Julio S G Montaner Journal: Am J Epidemiol Date: 2010-07-28 Impact factor: 4.897
Authors: Simona Di Giambenedetto; Laura Bracciale; Manuela Colafigli; Manuela Colatigli; Paola Cattani; Carmen Pinnetti; Carmen Pannetti; Alessandro Bacarelli; Mattia Prosperi; Giovanni Fadda; Roberto Cauda; Andrea De Luca Journal: Antivir Ther Date: 2007
Authors: Vikram S Gill; Viviane D Lima; Wen Zhang; Brian Wynhoven; Benita Yip; Robert S Hogg; Julio S G Montaner; P Richard Harrigan Journal: Clin Infect Dis Date: 2010-01-01 Impact factor: 9.079
Authors: Mari M Kitahata; Stephen J Gange; Alison G Abraham; Barry Merriman; Michael S Saag; Amy C Justice; Robert S Hogg; Steven G Deeks; Joseph J Eron; John T Brooks; Sean B Rourke; M John Gill; Ronald J Bosch; Jeffrey N Martin; Marina B Klein; Lisa P Jacobson; Benigno Rodriguez; Timothy R Sterling; Gregory D Kirk; Sonia Napravnik; Anita R Rachlis; Liviana M Calzavara; Michael A Horberg; Michael J Silverberg; Kelly A Gebo; James J Goedert; Constance A Benson; Ann C Collier; Stephen E Van Rompaey; Heidi M Crane; Rosemary G McKaig; Bryan Lau; Aimee M Freeman; Richard D Moore Journal: N Engl J Med Date: 2009-04-01 Impact factor: 91.245
Authors: Viktor von Wyl; Sabine Yerly; Jürg Böni; Philippe Bürgisser; Thomas Klimkait; Manuel Battegay; Hansjakob Furrer; Amalio Telenti; Bernard Hirschel; Pietro L Vernazza; Enos Bernasconi; Martin Rickenbach; Luc Perrin; Bruno Ledergerber; Huldrych F Günthard Journal: Arch Intern Med Date: 2007-09-10
Authors: Rajesh T Gandhi; Karen T Tashima; Laura M Smeaton; Vincent Vu; Justin Ritz; Adriana Andrade; Joseph J Eron; Evelyn Hogg; Carl J Fichtenbaum Journal: J Infect Dis Date: 2020-04-07 Impact factor: 7.759
Authors: Jimmy Ma; Robin M Nance; Joseph A C Delaney; Bridget M Whitney; Laura Bamford; Ronnie M Gravett; Richard D Moore; Sonia Napravnik; Kenneth H Mayer; Jeffrey M Jacobson; Katerina Christopoulos; Greer A Burkholder; Jeanne Keruly; Joseph J Eron; Jeffrey Martin; Edward R Cachay; Michael S Saag; Heidi M Crane; Mari M Kitahata Journal: Clin Infect Dis Date: 2022-09-10 Impact factor: 20.999
Authors: Chloe Orkin; Pedro Cahn; Antonella Castagna; Brinda Emu; P Richard Harrigan; Daniel R Kuritzkes; Mark Nelson; Jonathan Schapiro Journal: HIV Med Date: 2022-03-16 Impact factor: 3.094